Type 2 diabetes mellitus and cardiovascular risk; what the pharmacotherapy can change through the epigenetics

References

• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
   PubMed Web of Science ®Google Scholar
• Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:653789.
   PubMedGoogle Scholar
• Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26:142–148.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): a prospective observational study. BMJ. 2000;321:405–412.
   PubMed Web of Science ®Google Scholar
• Khan SS, Butler J, Gheorghiade M. Management of comorbid diabetes mellitus and worsening heart failure. JAMA. 2014;311:2379–2380.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ho SM. Epigenetics meets endocrinology. J Mol Endocrinol. 2011;46:R11–R32.
   PubMed Web of Science ®Google Scholar
• Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007;128:635–638.
   PubMed Web of Science ®Google Scholar
• Jablonka E. Epigenetic epidemiology. Int J Epidemiol. 2004;33:929–935.
   PubMed Web of Science ®Google Scholar
• Mobbs CV. Glucose-induced transcriptional hysteresis: role in obesity, metabolic memory, diabetes, and aging. Front Endocrinol (Lausanne). 2018;9:232.
   PubMed Web of Science ®Google Scholar
• Ngondo RP, Carbon P. Transcription factor abundance controlled by an auto-regulatory mechanism involving a transcription start site switch. Nucleic Acids Res. 2014;42:2171–2184.
   PubMed Web of Science ®Google Scholar
• Re RN. A proposed mechanism for the Berecek phenomenon with implications for cardiovascular reprogramming. J Am Soc Hypertens. 2018;12:644–651.
   PubMed Web of Science ®Google Scholar
• Hsu C, Jaquet V, Gencoglu M, et al. Protein dimerization generates bistability in positive feedback loops. Cell Rep. 2016;16:1204–1210.
   PubMed Web of Science ®Google Scholar
• Rosen ED, Kaestner KH, Natarajan R, et al. Epigenetics and epigenomics: implications for diabetes and obesity. Diabetes. 2018;67:1923–1931.
   PubMed Web of Science ®Google Scholar
• Hanly DJ, Esteller M, Berdasco M. Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer? Philos Trans R Soc Lond B Biol Sci. 2018;373:20170074.
   PubMed Web of Science ®Google Scholar
• Ruvkun G. Molecular biology. Glimpses of a tiny RNA world. Science. 2001;294:797–799.
   PubMed Web of Science ®Google Scholar
• Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans. 2008;36:1224–1231.
   PubMed Web of Science ®Google Scholar
• Wei JW, Huang K, Yang C, et al. Non-coding RNAs as regulators in epigenetics (Review). Oncol Rep. 2017;37:3–9.
   PubMed Web of Science ®Google Scholar
• Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–230.
   PubMed Web of Science ®Google Scholar
• Guay C, Roggli E, Nesca V, et al. Diabetes mellitus, a microRNA-related disease? Transl Res. 2011;157:253–264.
   PubMed Web of Science ®Google Scholar
• Arnes L, Sussel L. Epigenetic modifications and long noncoding RNAs influence pancreas development and function. Trends Genet. 2015;3:290–299.
   Web of Science ®Google Scholar
• Bettin N, Oss Pegorar C, Cusanelli E. The emerging roles of TERRA in telomere maintenance and genome stability. Cells. 2019;8:246.
   PubMed Web of Science ®Google Scholar
• Morris KV, Chan SW, Jacobsen SE, et al. Small interfering RNA-induced transcriptional gene silencing in human cells. Science. 2004;305:1289–1292.
   PubMed Web of Science ®Google Scholar
• Taft RJ, Pang KC, Mercer TR, et al. Non-coding RNAs: regulators of disease. J Pathol. 2010;220:126–139.
   PubMed Web of Science ®Google Scholar
• Yu CY, Kuo HC. The emerging roles and functions of circular RNAs and their generation. J Biomed Sci. 2019;26:29.
   PubMed Web of Science ®Google Scholar
• Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011;123:2145–2156.
   PubMed Web of Science ®Google Scholar
• Illingworth RS, Bird AP. CpG islands-’a rough guide’. FEBS Lett. 2009;583:1713–1720.
   PubMed Web of Science ®Google Scholar
• Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;29(99):247–257.
   Web of Science ®Google Scholar
• Ito S, Kuraoka I. Epigenetic modifications in DNA could mimic oxidative DNA damage: a double-edged sword. DNA Repair (Amst). 2015;32:52–57.
   PubMed Web of Science ®Google Scholar
• Sommese L, Zullo A, Mancini FP, et al. Clinical relevance of epigenetics in the onset and management of type 2 diabetes mellitus. Epigenetics. 2017;12:401–415.
   PubMed Web of Science ®Google Scholar
• Tamkun JW, Deuring R, Scott MP, et al. Brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell. 1992;68:561–572.
   PubMed Web of Science ®Google Scholar
• Denis GV. Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov Med. 2010;10:489–499.
   PubMed Web of Science ®Google Scholar
• Escalante-Covarrubias Q, Aguilar-Arnal L. Environmental regulation of metabolism through the circadian clock. Curr Opin Toxicol. 2018;8:93–101.
   Google Scholar
• Berezin A. Epigenetics in heart failure phenotypes. BBA Clin. 2016;6:31–37.
   PubMedGoogle Scholar
• Belden WJ. Chromatin regulation and dynamics. Elsevier Inc; 2017; p. 399–416. DOI:https://doi.org/10.1016/B978-0-12-803395-1.00016-2.
   Google Scholar
• Pacheco-Bernal I, Becerril-Pérez F, Aguilar-Arnal L. Circadian rhythms in the three-dimensional genome: implications of chromatin interactions for cyclic transcription. Clin Epigenetics. 2019;11:79.
   PubMed Web of Science ®Google Scholar
• Trott AJ, Menet JS. Regulation of circadian clock transcriptional output by CLOCK:BMAL1. PLoS Genet. 2018;14:e1007156.
   PubMed Web of Science ®Google Scholar
• Azzi A, Evans JA, Leise T, et al. Network dynamics mediate circadian clock plasticity. Neuron. 2017;93:441–450.
   PubMed Web of Science ®Google Scholar
• Oh G, Ebrahimi S, Carlucci M, et al. Cytosine modifications exhibit circadian oscillations that are involved in epigenetic diversity and aging. Nat Commun. 2018;9:644.
   PubMed Web of Science ®Google Scholar
• West AC, Bechtold DA. The cost of circadian desynchrony: evidence, insights and open questions. Bioessays. 2015;37:777–788.
   PubMed Web of Science ®Google Scholar
• Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12(12):1048–1057.
   PubMed Web of Science ®Google Scholar
• Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154:430–441.
   PubMed Web of Science ®Google Scholar
• Naresh NU, Haynes CM. Signaling and regulation of the mitochondrial unfolded protein response. Cold Spring Harb Perspect Biol. 2019;11:pii: a033944.
   PubMed Web of Science ®Google Scholar
• Tian Y, Garcia G, Bian Q, et al. Mitochondrial stress induces chromatin reorganization to promote longevity and UPRmt. Cell. 2016;165:1197–1208.
   PubMed Web of Science ®Google Scholar
• Godfrey KM, Barker DJ. Fetal programming and adult health. Public Health Nutr. 2001;4:611–624.
   PubMedGoogle Scholar
• Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. N Engl J Med. 1976;295:349–353.
   PubMed Web of Science ®Google Scholar
• Gluckman PD, Hanson MA, Buklijas T, et al. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol. 2009;5:401–408.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Why syndrome X? From harold himsworth to the insulin resistance syndrome. Cell Metab. 2005;1:9–14.
   PubMed Web of Science ®Google Scholar
• Brunton S. Pathophysiology of type 2 diabetes: the evolution of our understanding. J Fam Pract. 2016 Apr;65(4Suppl):pii: supp_az_0416.
   PubMedGoogle Scholar
• Kuroda A, Rauch TA, Todorov I, et al. Insulin gene expression is regulated by DNA methylation. PloS One. 2009;4:e6953.
   PubMed Web of Science ®Google Scholar
• Yang BT, Dayeh TA, Kirkpatrick CL, et al. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. Diabetologia. 2011;54:360–367.
   PubMed Web of Science ®Google Scholar
• Nilsson E, Jansson PA, Perfilyev A, et al. Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. Diabetes. 2014;63:2962–2976.
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Taleb S, Mallat Z, et al. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969–979.
   PubMed Web of Science ®Google Scholar
• Beekman M, Heijmans B, Martin N, et al. Heritabilities of apolipoprotein and lipid levels in three countries. Twin Res. 2002;5:87–97.
   PubMedGoogle Scholar
• Sayols-Baixeras S, Irvin MR, Arnett DK, et al. Epigenetics of Lipid Phenotypes. Curr Cardiovasc Risk Rep. 2016;10:31.
   PubMed Web of Science ®Google Scholar
• Lim M, Park L, Shin G, et al. Induction of apoptosis of beta cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus. Ann N Y Acad Sci. 2008;1150:311–315.
   PubMed Web of Science ®Google Scholar
• Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology. 2011;140:1729–1737.
   PubMed Web of Science ®Google Scholar
• Dávila LA, Pirela VB, Díaz W, et al. The microbiome and the epigenetics of diabetes mellitus. In: Waisundara V, editor. Diabetes food plan. Rijeka: IntechOpen; 2018. DOI:https://doi.org/10.5772/intechopen.76201
   Google Scholar
• Farrelly LA, Thompson RE, Zhao S, et al. Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature. 2019;567:535–539.
   PubMed Web of Science ®Google Scholar
• Roche E, Assimacopoulos-Jeannet F, Witters LA, et al. Induction by glucose of genes coding for glycolytic enzymes in a pancreatic beta-cell line (INS-1). J Biol Chem. 1997;272:3091–3098.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Agostinis P, Krysko O, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011;32:157–164.
   PubMed Web of Science ®Google Scholar
• Berezin AE. Endothelial progenitor cells dysfunction and impaired tissue reparation: the missed link in diabetes mellitus development. Diabetes Metab Syndr. 2017;11:215–220.
   PubMed Web of Science ®Google Scholar
• Paneni F, Mocharla P, Akhmedov A, et al. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res. 2012;111:278–289.
   PubMed Web of Science ®Google Scholar
• Simmons RA. Role of metabolic programming in the pathogenesis of beta-cell failure in postnatal life. Rev Endocr Metab Disord. 2007;8:95–104.
   PubMed Web of Science ®Google Scholar
• Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA. 2003;100:8466–8471.
   PubMed Web of Science ®Google Scholar
• Ortega FJ, Moreno M, Mercader JM, et al. Inflammation triggers specific microRNA profiles in human adipocytes and macrophages and their supernatants. Clin Epigenetics. 2015;7:49.
   PubMed Web of Science ®Google Scholar
• Lu B, Antoine DJ, Kwan K, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci USA. 2014;111:3068–3073.
   PubMed Web of Science ®Google Scholar
• Huebener P, Pradere JP, Hernandez C, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015;125:539–550.
   PubMed Web of Science ®Google Scholar
• Ribel-Madsen R, Fraga MF, Jacobsen S, et al. Genome-wide analysis of DNA methylation differences in muscle and fat from monozygotic twins discordant for type 2 diabetes. PLoS One. 2012;7:e51302.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–1535.
   PubMed Web of Science ®Google Scholar
• Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood. 2014;123:2768–2776.
   PubMed Web of Science ®Google Scholar
• Carubbi F, Alunno A, Gerli R, et al. Post-translational modifications of proteins: novel insights in the autoimmune response in rheumatoid arthritis. Cells. 2019;8:657.
   PubMed Web of Science ®Google Scholar
• Slack JL, Causey CP, Thompson PR. Protein arginine deiminase 4: a target for epigenetic cancer therapy. Cell Mol Life Sci. 2011;68:709–720.
   PubMed Web of Science ®Google Scholar
• Ma YH, Ma TT, Wang C, et al. High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation. Arthritis Res Ther. 2016;18:2.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou X, Yin Y, et al. Hyperglycemia induces neutrophil extracellular traps formation through an NADPH oxidase-dependent pathway in diabetic retinopathy. Front Immunol. 2019;9:3076.
   PubMed Web of Science ®Google Scholar
• Joshi MB, Baipadithaya G, Balakrishnan A, et al. Elevated homocysteine levels in type 2 diabetes induce constitutive neutrophil extracellular traps. Sci Rep. 2016;6:36362.
   PubMed Web of Science ®Google Scholar
• Brasacchio D, Okabe J, Tikellis C, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009;58:1229–1236.
   PubMed Web of Science ®Google Scholar
• Berezin A. Neutrophil extracellular traps: the core player in vascular complications of diabetes mellitus. Diabetes Metab Syndr. 2018:pii: S1871–4021: 30275–3.
   PubMed Web of Science ®Google Scholar
• Dos Santos Nunes MK, Silva AS, de Queiroga Evangelista IW, et al. Hypermethylation in the promoter of the MTHFR gene is associated with diabetic complications and biochemical indicators. Diabetol Metab Syndr. 2017;9:84.
   PubMed Web of Science ®Google Scholar
• Huang T, Ren J, Huang J, et al. Association of homocysteine with type 2 diabetes: a meta-analysis implementing Mendelian randomization approach. BMC Genomics. 2013;14:867.
   PubMed Web of Science ®Google Scholar
• Patterson S, Flatt PR, Brennan L, et al. Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic beta-cell glucose metabolism and insulin secretion. J Endocrinol. 2006;189:301–310.
   PubMed Web of Science ®Google Scholar
• Mishra PK, Tyagi N, Sen U, et al. Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol. Cardiovasc Diabetol. 2010;9:49.
   PubMed Web of Science ®Google Scholar
• Castro R, Rivera I, Struys EA, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem. 2003;49:1292–1296.
   PubMed Web of Science ®Google Scholar
• Suzuki LA, Poot M, Gerrity RG, et al. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes. 2001;50:851–860.
   PubMed Web of Science ®Google Scholar
• Zaina S, Heyn H, Carmona FJ, et al. DNA methylation map of human atherosclerosis. Circ Cardiovasc Genet. 2014;7:692–700.
   PubMedGoogle Scholar
• Valencia-Morales Model P, Zaina S, Heyn H, et al. The DNA methylation drift of the atherosclerotic aorta increases with lesion progression. BMC Med Genomics. 2015;8:7.
   PubMed Web of Science ®Google Scholar
• Pirola L, Balcerczyk A, Tothill RW, et al. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Res. 2011;21:1601–1615.
   PubMed Web of Science ®Google Scholar
• Breton CV, Park C, Siegmund K, et al. NOS1 methylation, and carotid artery intima-media thickness in children. Circ Cardiovasc Genet. 2014;7:116–122.
   PubMedGoogle Scholar
• Valente AJ, Yoshida T, Murthy SN, et al. Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol. 2012;303:H282–96.
   PubMed Web of Science ®Google Scholar
• Pons D, de Vries FR, van Den Elsen PJ, et al. Epigenetic histone acetylation modifiers in vascular remodeling: new targets for therapy in cardiovascular disease. Eur Heart J. 2009;30:266–277.
   PubMed Web of Science ®Google Scholar
• Fang YC, Yeh CH. Role of microRNAs in vascular remodeling. Curr Mol Med. 2015;15:684–696.
   PubMed Web of Science ®Google Scholar
• Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810–817.
   PubMed Web of Science ®Google Scholar
• Muller M, Fasching P, Schmid R, et al. Inhibition of paracrine angiotensin-converting enzyme in vivo: effects on interstitial glucose and lactate concentrations in human skeletal muscle. Eur J Clin Invest. 1997;27:825–830.
   PubMed Web of Science ®Google Scholar
• Lupi R, Del Guerra S, Bugliani M, et al. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol. 2006;154:355–361.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Ura N, Takizawa H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens. 2004;22:1977–1982.
   PubMed Web of Science ®Google Scholar
• Frossard M, Joukhadar C, Steffen G, et al. Paracrine effects of angiotensin-converting-enzyme- and angiotensin-II-receptor- inhibition on transcapillary glucose transport in humans. Life Sci. 2000;66:PL147–54.
   PubMed Web of Science ®Google Scholar
• Folli F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes. 1999;107:133–139.
   PubMed Web of Science ®Google Scholar
• De Mello WC. Chemical communication between heart cells is disrupted by intracellular renin and angiotensin II: implications for heart development and disease. Front Endocrinol (Lausanne). 2015;6:72.
   PubMed Web of Science ®Google Scholar
• Sparks MA, Crowley SD, Gurley SB, et al. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4:1201–1228.
   PubMed Web of Science ®Google Scholar
• Pentz ES, Lopez ML, Cordaillat M, et al. Identity of the renin cell is mediated by cAMP and chromatin remodeling: an in vitro model for studying cell recruitment and plasticity. Am J Physiol Heart Circ Physiol. 2008;294:H699–707.
   PubMed Web of Science ®Google Scholar
• Mudersbach T, Siuda D, Kohlstedt K, et al. Epigenetic control of the angiotensin-converting enzyme in endothelial cells during inflammation. PLoS One. 2019;14:e0216218. Published. 2019 May 1.
   PubMed Web of Science ®Google Scholar
• Krop M, Lu X, Danser AH, et al. The (pro)renin receptor. A decade of research: what have we learned? Pflugers Arch. 2013;465:87–97.
   PubMed Web of Science ®Google Scholar
• Nguyen G, Delarue F, Burcklé C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417–1427.
   PubMed Web of Science ®Google Scholar
• Karnik SS, Unal H, Kemp JR, et al. International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected] [published correction appears in pharmacol rev. 2015;67:820]. Pharmacol Rev. 2015;67:754–819.
   PubMed Web of Science ®Google Scholar
• Re RN, Cook JL. Noncanonical intracrine action. J Am Soc Hypertens. 2011;5:435–448.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang X, Vikash V, et al. ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev. 2016;2016:4350965.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Yoshika M, Komiyama Y, et al. The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain. Hypertens Res. 2011;34:1147–1160.
   PubMed Web of Science ®Google Scholar
• Takeda Y, Demura M, Wang F, et al. Epigenetic regulation of aldosterone synthase gene by sodium and angiotensin II. J Am Heart Assoc. 2018;7:e008281.
   PubMed Web of Science ®Google Scholar
• Lim HS, MacFadyen RJ, Lip GY. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med. 2004;164:1737–1748.
   PubMed Web of Science ®Google Scholar
• DREAM Trial Investigators, Dagenais GR, Gerstein HC, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31:1007–1014.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477–1490.
   PubMed Web of Science ®Google Scholar
• van der Meer P, Gaggin HK, Dec GW. ACC/AHA versus ESC guidelines on heart failure: JACC guideline comparison. J Am Coll Cardiol. 2019;4(73):2756–2768.
   Google Scholar
• Tsujimoto T, Kajio H, Shapiro MF, et al. Risk of all-cause mortality in diabetic patients taking β-blockers. Mayo Clin Proc. 2018;93:409–418.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med. 2007;24:626–634.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279–1289.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J. 2013;166:217–23 e11.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380:347–357.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Holst AG, Semaglutide VT. Cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2017;376:891–892.
   PubMed Web of Science ®Google Scholar
• Yu X, Mao W, Zhai Y, et al. Anti-tumor activity of metformin: from metabolic and epigenetic perspectives. Oncotarget. 2017;8:5619–5628.
   PubMedGoogle Scholar
• Giglio RV, Volti GL, Nikolic D, et al. Liraglutide increases circulating miR-27b, miR-130a and miR-210 inpatients with type 2 diabetes: a 4-month pilot study. Diabetologia. 2016;59:S380.
   Web of Science ®Google Scholar
• Ghanaat-Pour H, Sjoholm A. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity. Diabetes Metab Res Rev. 2009;25:163–184.
   PubMed Web of Science ®Google Scholar
• Du Y, Zheng H, Wang J, et al. Metformin inhibits histone H2B monoubiquitination and downstream gene transcription in human breast cancer cells. Oncol Lett. 2014;8:809–812.
   PubMed Web of Science ®Google Scholar
• Yan L, Zhou J, Gao Y, et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015;34:3076–3084.
   PubMed Web of Science ®Google Scholar
• Zhong T, Men Y, Lu L, et al. Metformin alters DNA methylation genome-wide via the H19/SAHH axis. Oncogene. 2017;36:2345–2354.
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Tsunekawa S, Ikeniwa M, et al. Long-term pancreatic beta cell exposure to high levels of glucose but not palmitate induces DNA methylation within the insulin gene promoter and represses transcriptional activity. PloS One. 2015;10:e0115350.
   PubMed Web of Science ®Google Scholar
• Elbere I, Silamikelis I, Ustinova M, et al. Significantly altered peripheral DNA methylation profile as a result of the immediate effect of metformin use in healthy individuals. Clin Epigenetics. 2018;10:156.
   PubMed Web of Science ®Google Scholar
• Garcia-Calzon S, Perfilyev A, Mannisto V, et al. Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver. Clin Epigenetics. 2017;9:102.
   PubMed Web of Science ®Google Scholar
• Legchenko E, Chouvarine P, Borchert P, et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018;438:eaao0303.
   Web of Science ®Google Scholar
• Aouali N, Palissot V, El-Khoury V, et al. Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells. Br J Haematol. 2009;147:662–671.
   PubMed Web of Science ®Google Scholar
• Aouali N, Broukou A, Bosseler M, et al. Epigenetic activity of peroxisome proliferator-activated receptor gamma agonists increases the anticancer effect of histone deacetylase inhibitors on multiple myeloma cells. PloS One. 2015;10:e0130339.
   PubMed Web of Science ®Google Scholar
• Li YF, Langholz B, Salam MT, et al. Maternal and grandmaternal smoking patterns are associated with early childhood asthma. Chest. 2005;127:1232–1241.
   PubMed Web of Science ®Google Scholar
• Leslie FM. Multigenerational epigenetic effects of nicotine on lung function. BMC Med. 2013;11:27.
   PubMed Web of Science ®Google Scholar
• Pharaon LF, El-Orabi NF, Kunhi M, et al. Rosiglitazone promotes cardiac hypertrophy and alters chromatin remodeling in isolated cardiomyocytes. Toxicol Lett. 2017;280:151–158.
   PubMed Web of Science ®Google Scholar
• Aumueller E, Remely M, Baeck H, et al. Interleukin-6 CpG methylation and body weight correlate differently in type 2 diabetes patients compared to obese and lean controls. J Nutrigenet Nutrigenomics. 2015;8:26–35.
   PubMed Web of Science ®Google Scholar
• Gao M, Deng XL, Liu ZH, et al. Liraglutide protects beta-cell function by reversing histone modification of Pdx-1 proximal promoter in catch-up growth male rats. J Diabetes Complications. 2018;32:985–994.
   PubMed Web of Science ®Google Scholar
• Pinney SE, Jaeckle Santos LJ, Han Y, et al. Exendin-4 increases histone acetylase activity and reverses epigenetic modifications that silence Pdx1 in the intrauterine growth retarded rat. Diabetologia. 2011;54:2606–2614.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Mizukami K, Hayashi M, et al. Exendin-4 promotes extracellular-superoxide dismutase expression in A549 cells through DNA demethylation. J Clin Biochem Nutr. 2016;58:34–39.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Ohashi A, Nishida S, et al. Exendin-4 induces extracellular-superoxide dismutase through histone H3 acetylation in human retinal endothelial cells. J Clin Biochem Nutr. 2016;59:174–181.
   PubMed Web of Science ®Google Scholar
• Cicek FA, Tokcaer-Keskin Z, Ozcinar E, et al. Dipeptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation. Mol Biol Rep. 2014;41:4853–4863.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Watanabe A, Tanaka M, et al. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4. J Pharmacol Sci. 2019;139:112–119.
   PubMed Web of Science ®Google Scholar
• Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370–385.
   PubMed Web of Science ®Google Scholar
• Mansuri A, Elmaghrabi A, Alhamoud I, et al. Transient enalapril attenuates the reduction in glomerular filtration rate in prenatally programmed rats. Physiol Rep. 2017;5:e13266.
   PubMed Web of Science ®Google Scholar
• De Vries N, Prestes P, Rana I, et al. Epigenetic changes after acute treatment with acute angiotensin-converting enzyme inhibitors (ACEi). J Hypertens. 2016;34:e204–e205.
   PubMed Web of Science ®Google Scholar
• De Vries N, Prestes P, Raipuria M, et al. Angiotensin-converting enzyme inhibitors epigenetically attenuate telomere shortening. J Hypertens. 2018;36:85.
   PubMed Web of Science ®Google Scholar
• Ali MM, Mahmoud AM, Le Master E, et al. Role of matrix metalloproteinases and histone deacetylase in oxidative stress-induced degradation of the endothelial glycocalyx. Am J Physiol Heart Circ Physiol. 2019;316:H647–H663.
   PubMed Web of Science ®Google Scholar
• Masjoan-Juncos JX, Liao T-D, Bordcoch G, et al. Offspring of captopril treated spontaneously hypertensive rats have lower angiotensin II Type 1 receptor expression which is associated with lower blood pressure. Hypertension. 2017;70. Accessed 2019 Jun 13 https://insights.ovid.com/hypertension/hype/2017/09/001/abstract-p231-offspring-captopril-treated/275/00004268
   Web of Science ®Google Scholar
• Adetoro IA, Lucchesi PA, Cismowski M, et al. The prenatal renin-angiotensin system during a critical period in the development of hypertensive heart disease. Faseb J. 2016;30.
   Web of Science ®Google Scholar
• Wang T, Lian G, Cai X, et al. Effect of prehypertensive losartan therapy on AT1R and ATRAP methylation of adipose tissue in the later life of high fat fed spontaneously hypertensive rats. Mol Med Rep. 2018;17:1753–1761.
   PubMed Web of Science ®Google Scholar
• Reddy MA, Sumanth P, Lanting L, et al. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int. 2014;85:362–373.
   PubMed Web of Science ®Google Scholar
• Park HW, Kim Y, Kim KH, et al. Angiotensin II receptor blocker pretreatment of rats undergoing sudden renal ablation. Nephrol Dialysis Transplant. 2012;27:107–114.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhang F, Ning Q. Losartan reverses the down-expression of long noncoding RNA-NR024118 and Cdkn1c induced by angiotensin II in adult rat cardiac fibroblasts. Pathol Biol. 2015;63:122–125.
   PubMedGoogle Scholar
• Wang J, Duan L, Gao Y, et al. Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice. Mol Cell Endocrinol. 2018;472:149–158.
   PubMed Web of Science ®Google Scholar
• Kadakol A, Malek V, Goru SK, et al. Telmisartan and esculetin combination improve type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications. Indian J Pharmacol. 2017;49:348–356.
   PubMed Web of Science ®Google Scholar
• Malek V, Gaikwad AB. Telmisartan and thiorphan combination treatment attenuate fibrosis and apoptosis in preventing diabetic cardiomyopathy. Cardiovasc Res. 2019;115:373–384.
   PubMed Web of Science ®Google Scholar
• Pandey A, Goru SK, Kadakol A, et al. H2AK119 monoubiquitination regulates Angiotensin II receptor-mediated macrophage infiltration and renal fibrosis in type 2 diabetic rats. Biochimie. 2016;131:68–76.
   PubMed Web of Science ®Google Scholar
• Pandey A, Gaikwad AB. Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase-mediated apoptosis. Biochem Biophys Res Commun. 2017;487:827–833.
   PubMed Web of Science ®Google Scholar
• Yue Z, Yun-Shan Z, Feng-Xia X. miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan. J Renin Angiotensin Aldosterone Syst. 2016;17:1470320316663327.
   Web of Science ®Google Scholar
• Kaneko M, Satomi T, Fujiwara S, et al. AT1 receptor blocker azilsartan medoxomil normalizes plasma miR-146a and miR-342-3p in a murine heart failure model. Biomarkers. 2017;22:253–260.
   PubMed Web of Science ®Google Scholar